← brief for 2026-09-17 · Slowing decline

Initial Changes in eGFR during Treatment with Balcinrenone and Dapagliflozin

Article B Peer reviewed Small trial

Key takeaways

This study looked at 324 people with kidney disease who started a new drug combo. It checked how their kidney filtering rate changed in the first few weeks. The goal was to see if the drop in function was safe and expected.

Who did this work

Hiddo J.L. Heerspink (University Medical Center Groningen) · Erika De Sousa Amorim (AstraZeneca (Poland)) · Jelle M. Beernink (University Medical Center Groningen) · Özkan Güngör (Kahramanmaraş Sütçü İmam University) · Anna L. Eriksson (AstraZeneca (Finland)) · Nicolás Guzmán (AstraZeneca (Poland)) · Yunyun Jiang (AstraZeneca (Spain)) · Martin Fredholm (AstraZeneca (Italy)) · Judith Hartleib-Geschwindner (AstraZeneca (Finland)) · Maria Leonsson‐Zachrisson (AstraZeneca (Finland)) · Patrick B. Mark (University of Glasgow)

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-17
https://doi.org/10.2215/cjn.0000001202